Third trimester fetal pulmonary artery Doppler blood flow velocity characteristics following prenatal selective serotonin reuptake inhibitor (SSRI) exposure

Early Human Development

Volumn 88, Issue 8, 2012, Pages 609-615

  Lim, Ken ^a,b   Sanders, Ari ^b   Brain, Ursula ^a,b   Riggs, Wayne ^a   Oberlander, Tim F ^a,b   Rurak, Dan ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Fetus; Pregnancy; Pulmonary blood flow; SSRI antidepressants

Indexed keywords

CITALOPRAM; FLUOXETINE; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADULT; ARTICLE; BLOOD FLOW VELOCITY; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG BLOOD LEVEL; FEMALE; FETUS; GESTATIONAL AGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LUNG ARTERY; MAJOR CLINICAL STUDY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; PULSATILITY INDEX; RESISTANCE INDEX; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY; VENOUS BLOOD;

ADULT; BLOOD FLOW VELOCITY; DEPRESSION; FEMALE; HUMANS; INFANT, NEWBORN; MALE; MATERNAL EXPOSURE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, THIRD; PULMONARY ARTERY; SEROTONIN UPTAKE INHIBITORS; ULTRASONOGRAPHY, DOPPLER; ULTRASONOGRAPHY, PRENATAL;

EID: 84863779007     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2012.01.004     Document Type: Article

References (57)

1. Evans J., Heron J., Francomb H., Oke S., Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001, 323:257-260.
2. Wisner K.L., Sit D.K., Hanusa B.H., Moses-Kolko E.L., Bogen D.L., Hunker D.F., et al. Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166:557-566.
3. Toh S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S. Selective serotonin reuptake inhibitor use and risk of gestational hypertension. Am J Psychiatry 2009, 166:320-328.
4. Toh S., Mitchell A.A., Louik C., Werler M.M., Chambers C.D., Hernandez-Diaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009, 29:555-560.
5. Chambers C.D., Johnson K.A., Dick L.N., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Eng J Med 1996, 335:1010-1015.
6. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63(8):898-906.
7. Oberlander T.F., Misri S., Fitzgerald C.E., Kostaras X., Rurak D., Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004, 65:230-237.
8. Oberlander T.F., Grunau R.E., Fitzgerald C., Ellwood E.-L., Misri S., Rurak D., et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002, 51:443-453.
9. Oberlander T.F., Grunau R., Mayes L., Riggs W., Rurak D., Papsdorf M., et al. Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure. Early Hum Dev 2008, 84:689-697.
10. Steinhorn R.H. Neonatal pulmonary hypertension. Pediatr Crit Care Med 2010, 11:S79-S84. [Suppl].
11. Chambers C.D., Hernandez-Diaz S., Van Marter L.J., Werler M.M., Louik C., Jones K.L., et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:579-587.
12. Kallen B., Olausson P.O. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008, 17:801-806.
13. Andrade S.E., McPhillips H., Loren D., Raebel M.A., Lane K., Livingston J., et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009, 18:246-252.
14. Wichman C.L., Moore K.M., Lang T.R., St Sauver J.L., Heise R.H., Watson W.J. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009, 84:23-27.
15. Wilson K.L., Zelig C.M., Harvey J.P., Cunningham B.S., Dolinsky B.M., Napolitano P.G. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2010, 28:19-24.
16. Fornaro E., Li D., Pan J., Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007, 176:1035-1040.
17. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005, 111:2812-2819.
18. Li X.Q., Hong Y., Wang Y., Zhang X.H., Wang H.L. Sertraline protects against monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2006, 33:1047-1051.
19. Kawut S.M., Horn E.M., Berekashvili K.K., Lederer D.J., Widlitz A.C., Rosenzweig E.B., et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006, 19:370-374.
20. Abman S.H., Accurso F.J. Acute effects of partial compression of ductus arteriosus on fetal pulmonary circulation. Am J Physiol 1989, 257:H626-H634.
21. Grover T.R., Parker T.A., Balasubramaniam V., Markham N.E., Abman S.H. Pulmonary hypertension impairs alveolarization and reduces lung growth in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2005, 288:L648-L654.
22. Soifer S.J., Kaslow D., Roman C., Heymann M.A. Umbilical cord compression produces pulmonary hypertension in newborn lambs: a model to study the pathophysiology of persistent pulmonary hypertension in the newborn. J Dev Physiol 1987, 9:239-252.
23. Bixby C.E., Ibe B.O., Abdallah M.F., Zhou W., Hislop A.A., Longo L.D., et al. Role of platelet-activating factor in pulmonary vascular remodeling associated with chronic high altitude hypoxia in ovine fetal lambs. Am J Physiol Lung Cell Mol Physiol 2007, 293:L1475-L1482.
24. Thornburg K.L., Morton M.J. Filling and arterial pressures as determinants of RV stroke volume in the sheep fetus. Am J Physiol 1983, 244:H656-H663.
25. Reller M.D., Morton M.J., Reid D.L., Thornburg K.L. Fetal lamb ventricles respond differently to filling and arterial pressures and to in utero ventilation. Pediatr Res 1987, 22:621-626.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62.
27. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32:50-55.
28. Rurak D., Lim K., Sanders A., Brain U., Riggs W., Oberlander T.F. Third trimester fetal heart rate and doppler middle cerebral artery blood flow velocity characteristics during prenatal selective serotonin reuptake inhibitor exposure. Pediatr Res 2011, 70:96-101.
29. DeVane C.L. Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. Cell Mol Neurobiol 1999, 19:443-466.
30. Hiemke C.H.S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000, 85:11-28.
31. Rasanen J., Huhta J.C., Weiner S., Wood D.C., Ludomirski A. Fetal branch pulmonary arterial vascular impedance during the second half of pregnancy. Am J Obstet Gynecol 1996, 174:1441-1449.
32. Rasanen J., Wood D.C., Weiner S., Ludomirski A., Huhta J.C. Role of the pulmonary circulation in the distribution of human fetal cardiac output during the second half of pregnancy. Circulation 1996, 94:1068-1073.
33. Laudy J.A., de Ridder M.A., Wladimiroff J.W. Human fetal pulmonary artery velocimetry: repeatability and normal values with emphasis on middle and distal pulmonary vessels. Ultrasound Obstet Gynecol 2000, 15:479-486.
34. Mielke G., Benda N. Cardiac output and central distribution of blood flow in the human fetus. Circulation 2001, 103:1662-1668.
35. Tan J., Silverman N.H., Hoffman J.I., Villegas M., Schmidt K.G. Cardiac dimensions determined by cross-sectional echocardiography in the normal human fetus from 18 weeks to term. Am J Cardiol 1992, 70:1459-1467.
36. Katayama S., Tada K., Nakanishi Y., Takata M., Kumazawa K., Tsukahara S., et al. Evaluation of normal fetal branch pulmonary artery diameters measured by ultrasonography: a comparison with congenital diaphragmatic hernia. Fetal Diagn Ther 2008, 23:303-307.
37. Sokol J., Shimizu N., Bohn D., Doherty D., Ryan G., Hornberger L.K. Fetal pulmonary artery diameter measurements as a predictor of morbidity in antenatally diagnosed congenital diaphragmatic hernia: a prospective study. Am J Obstet Gynecol 2006, 195:470-477.
38. Macklon N.S., Laudy J.A., Mulder P.G., Wladimiroff J.W. Behavior-state-dependent changes in human fetal pulmonary blood flow velocity waveforms. Obstet Gynecol 1999, 93:184-188.
39. Morrison J.L., Chien C., Gruber N., Rurak D., Riggs K.W. Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Dev Brain Res 2001, 131:47-56.
40. Abman S.H., Shanley P.F., Accurso F.J. Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 1989, 83:1849-1858.
41. Belik J., Keeley F.W., Baldwin F., Rabinovitch M. Pulmonary hypertension and vascular remodeling in fetal sheep. Am J Physiol 1994, 266:H2303-H2309.
42. Jouannic J.M., Roussin R., Hislop A.A., Lanone S., Martinovic J., Boczkowski J., et al. Systemic arteriovenous fistula leads to pulmonary artery remodeling and abnormal vasoreactivity in the fetal lamb. Am J Physiol 2003, 285:L701-L709.
43. Moses-Kolko E.L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005, 293:2372-2383.
44. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63:898-906.
45. Oberlander T.F., Warburton W., Misri S., Aghajanian J., Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008, 192:338-343.
46. Fabaroff and martin's neonatal-perinatal medicine 2011, Mosby Elsevier, Philadelphia, PA. 9th ed. J.M. Richard, A.A. Fanaroff, M.C. Walsh (Eds.).
47. Riskin A., Abend-Weinger M., Riskin-Mashiah S., Kugelman A., Bader D. Cesarean section, gestational age, and transient tachypnea of the newborn: timing is the key. Am J Perinatol 2005, 22:377-382.
48. Yurdakok M. Transient tachypnea of the newborn: what is new?. J Matern Fetal Neonatal Med 2010, 23(Suppl. 3):24-26.
49. Derbent A., Tatli M.M., Duran M., Tonbul A., Kafali H., Akyol M., et al. Transient tachypnea of the newborn: effects of labor and delivery type in term and preterm pregnancies. Arch Gynecol Obstet 2011, 283:947-951.
50. Chua B.A., Perks A.M. The pulmonary neuroendocrine system and drainage of the fetal lung: effects of serotonin. Gen Comp Endocrinol 1999, 113:374-387.
51. Laine K., Heikkinen T., Ekblad U., Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003, 60:720-726.
52. Cutz E., Yeger H., Pan J. Pulmonary neuroendocrine cell system in pediatric lung disease-recent advances. Pediatr Dev Pathol 2007, 10:419-435.
53. Pan J., Copland I., Post M., Yeger H., Cutz E. Mechanical stretch-induced serotonin release from pulmonary neuroendocrine cells: implications for lung development. Am J Physiol 2006, 290:L185-L193.
54. Marcos E., Fadel E., Sanchez O., Humbert M., Dartevelle P., Simonneau G., et al. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res 2004, 94:1263-1270.
55. Oberlander T.F., Bonaguro R.J., Misri S., Papsdorf M., Ross C.J., Simpson E.M. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008, 13:65-73.
56. Horstmann S., Binder E.B. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009, 124:57-73.
57. Murphy D.L., Moya P.R. Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. Curr Opin Pharmacol 2011, 11:3-10.